Overview

Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)

Status:
Completed

Trial end date:
2015-04-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to confirm that Ulinastatin is a safe and effective drug and it can reduce the incidence of postoperative hepatic failure in HCC patients. To evaluate that Ulinastatin can improve survival in HCC patients or not.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Eastern Hepatobiliary Surgery Hospital

Treatments:

Glycyrrhizic Acid
Urinastatin

Criteria

Inclusion Criteria:

1. Male or female patients > 35 years and <=55 years of age.

2. confirmed case (patients with HCC)

3. Tumors can be radical removed and resection volume was 50% to 70%.

4. Criteria of liver function: Child A level, serum bilirubin ≤ 1.5 times the upper limit
of normal value,alanine aminotransferase and aspartate aminotransferase ≤ 2 times the
upper limit of normal value.

5. No dysfunction in major organs; Blood routine, kidney function, cardiac function and
lung function are basically normal. Hbg ≥ 90g/L, WBC ≥ 3.000 cells/mm³,platelets ≥
80.000 cells/mm³.

6. Karnofsky Performance Score performance over 60.

7. Patients who can understand this trial and have signed information consent.

Exclusion Criteria:

1. Patients who have undergone previous treatment by Ulinastatin.

2. Patients with apparent cardiac, pulmonary, cerebronic and renal dysfunction, which may
affect the treatment of liver cancer.

3. Patients with other diseases which may affect the treatment mentioned here.

4. Patients with medical history of other malignant tumors.

5. Subjects participating in other clinical trials.

6. Extrahepatic metastasis, portal vein or other major vascular involvement. liver
function: Child B C.

7. Patients would not sign the consent to the trial.